Telehealth & Digital Health

A new report shows most medical practices are flying blind, with only 7% confident in tracking revenue, leading to massive, preventable financial losses.

Despite missing its primary goal, Cadrenal Therapeutics' drug CAD-1005 drastically cut deadly blood clots, setting up a crucial FDA meeting for a new path forward.

With double-digit growth, a new AI-focused CTO, and major investor backing, XiFin is poised to redefine healthcare's complex financial future.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

With a promise of cellular renewal via exosomes, (plated) Skin Science is leading a biotech revolution. But can it navigate the hype and regulatory hurdles?

Amidst industry-wide regulatory challenges, Meridian secures critical IVDR certification for its Alethia assays, ensuring continued market access in Europe.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

With its Moda-flx system cleared by the FDA, Diality hires M&A expert Peter Donato to navigate the path to commercialization in the $92B dialysis market.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

After an 8-year hiatus, Elizabeth Arden launches Eternal Aura. A look at the strategy combining a new star, wellness science, and heritage to reclaim its spot.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

As Legacy Community Health embarks on a historic expansion, new COO Aaron Stewart is tasked with steering Texas's largest FQHC to serve more communities.

Beyond prize money, CharmHealth's annual challenge builds an ecosystem for healthtech startups, offering a direct path from AI-driven ideas to market impact.

After gaining FDA alignment, INmune Bio is advancing its inflammation-targeting drug, XPro1595, offering a novel and potentially safer approach for patients.

The AI health platform's latest acquisition integrates a specialized pregnancy app, promising a new era of proactive, data-driven maternal care for families.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

Teva and Medincell’s once-monthly olanzapine injection shows promise in trials, potentially freeing patients from burdensome post-injection observation.

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.